. Author manuscript; available in PMC: 2017 Sep 10.

Published in final edited form as: J Pharm Biomed Anal. 2016 Jul 26;129:473–481. doi: 10.1016/j.jpba.2016.07.040

Table 5.

Summary of pharmacokinetic parameters of nanoformulated tenofovir and elvitegravir following single subcutaneous injection (100mg/kg each) to female humanized mice.

Parameter	Tenofovir	Elvitegravir
C_max (ng/mL)	264.90 ± 142.57	174.33 ± 150.14
AUC_all (day*ng/mL)	1433.34 ± 428.88	627.04 ± 450.73
Cl (L/h)	1.20	6.26
Vz_F_obs (L)	2122.56	2711.15
K_el (1/day)	0.0136	0.0554
t1/2 (Day)	50.97	12.50
AUC_all_Liver (day*ng/mL)	5065.08 ± 777.97	515.05 ± 238.25
AUC_all_Kidney (day*ng/mL)	988.04 ± 184.07	1693.72 ± 276.28